Tryvio (aprocitentan) nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product” - Idorsia

Idorsia  announced that The Galien Foundation, a premier global institution dedicated to honoring innovators in life sciences, has nominated  Tryvio (aprocitentan) in the category of “Best Pharmaceutical Product” in the 2025 Prix Galien USA awards. The winner will be announced during the Prix Galien USA Awards Ceremony on October 30, 2025. To qualify for the Prix Galien Award, each candidate must be FDA approved for marketing within the last five years and demonstrate tremendous potential to improve human health. The Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments. The Prix Galien was created in 1970 in honor of Galien,  a key figure in the development of modern research-based medicine. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Tryvio , the first systemic hypertension treatment to target a new pathway in over 30 years, is a dual endothelin receptor antagonist (ERA) indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

Dr. Martine Clozel, Chief Scientific Officer and Head of Research at Idorsia, commented:  “We are very proud to have been nominated for this prestigious award. Tryvio is unique in many aspects. It is the result of many years of work on the endothelin pathway and represents a true therapeutic breakthrough with impressive clinical data. 

Tyrvio's blood pressure lowering effect was consistent in all studied subgroups of patients, and notably those whose hypertension is notoriously difficult to treat, such as  elderly patients and patients with obesity or diabetes. These patients sometimes remain hypertensive despite two, three, or more anti-hypertensive therapies. Plus, Tryvio provides significant blood pressure lowering for patients with hypertension and chronic kidney disease, a condition affecting millions of patients who are often underserved with the current guideline directed therapies, without risking aggravation of renal function or hyperkalemia.”